Artenimol
drugOn this page
Also known as .beta.-dihydroartemisininAlaxinArtemether related compound aArtenimolumCotecxinCotexinDi-hydroqinghaosuDihydroartemisinin.beta.-DihydroartemisinineDihydroqinghaosuDynamaxGNF-PF-5634SalaxinSantecxindihyroartemisinindihydroartimisinindihydroarteminisinDihydroartemisin
Summary
Artenimol (CHEMBL307261) is an approved small molecule (ATC P01BE05); indicated across 7 conditions including malaria and plasmodium falciparum malaria.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: P01BE05
- Indications: 7 conditions
- Clinical trials: 83
- Chemistry: 284.35 Da · C15H24O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL307261 |
| Name | Artenimol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 3000518 |
| ATC | P01BE05 |
| Molecular formula | C15H24O5 |
| Molecular weight | 284.35 |
| InChIKey | BJDCWCLMFKKGEE-ISOSDAIHSA-N |
SMILES: C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
IUPAC name: (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
Also known as: .beta.-dihydroartemisinin, Alaxin, Artemether related compound a, Artenimol, Artenimolum, Cotecxin, Cotexin, Di-hydroqinghaosu, Dihydroartemisinin, .beta.-, Dihydroartemisinine, Dihydroqinghaosu
Patent coverage: 11 distinct patent families (21 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin E synthase 2.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PTGES2 | 5.02 | IC50 | 9600 | nM | CHEMBL_ACT_25967627 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| malaria | 4 | MONDO:0005136 | EFO:0001068 |
| Plasmodium falciparum malaria | 3 | MONDO:0005920 | EFO:0007444 |
| Plasmodium vivax malaria | 3 | MONDO:0005921 | EFO:0007445 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| systemic lupus erythematosus | 2 | MONDO:0007915 | MONDO:0007915 |
| polycystic ovary syndrome | 2 | MONDO:0008487 | EFO:0000660 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 83.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 39 |
| PHASE3 | 17 |
| PHASE4 | 8 |
| PHASE2 | 8 |
| EARLY_PHASE1 | 5 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06068530 | PHASE4 | RECRUITING | Mass Vaccine and Drug Administration, Bangladesh |
| NCT07322068 | PHASE4 | NOT_YET_RECRUITING | Perennial Malaria Chemoprevention in the Malaria Vaccine Era |
| NCT00449917 | PHASE4 | COMPLETED | Visiobiane Anti-age Effects on Vision Parameters |
| NCT00634686 | PHASE4 | UNKNOWN | Effects of Omega-3 Fatty Acids on Bone and Frailty |
| NCT01887821 | PHASE4 | COMPLETED | Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam |
| NCT01930331 | PHASE4 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO |
| NCT04767191 | PHASE4 | COMPLETED | Malaria Therapeutic Efficacy Study (TES) Kenya |
| NCT05465135 | PHASE4 | COMPLETED | The Effect of Dihydroartemisinin in PCOS |
| NCT03965988 | PHASE3 | RECRUITING | Docosahexaenoic Acid on Breath Holding Spells in Children |
| NCT00266825 | PHASE3 | COMPLETED | DHA Supplementation and Pregnancy Outcome |
| NCT00345176 | PHASE3 | COMPLETED | Age-Related Eye Disease Study 2 (AREDS2) |
| NCT00351624 | PHASE3 | COMPLETED | Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age |
| NCT00517036 | PHASE3 | COMPLETED | Omega-3 Fatty Acids for Treating Adults With Major Depression |
| NCT00682578 | PHASE3 | COMPLETED | A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan |
| NCT01007110 | PHASE3 | COMPLETED | Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes |
| NCT01288820 | PHASE3 | COMPLETED | Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria |
| NCT01422317 | PHASE3 | COMPLETED | Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction |
| NCT01846325 | PHASE2/PHASE3 | COMPLETED | The Effects of Administration of Combined Docosahexaenoic Acid and Vitamin E Supplements on Spermatogram and Seminal Plasma Oxidative Stress in Infertile Men With Asthenozoospermia |
| NCT01883817 | PHASE3 | COMPLETED | Effect of Omega-3 Fatty Acid on Cortical Function in ADHD |
| NCT01899820 | PHASE3 | UNKNOWN | Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya |
| NCT01940640 | PHASE2/PHASE3 | COMPLETED | Effect of Mother DHA Supplementation on Premature Newborn. |
| NCT02057406 | PHASE3 | COMPLETED | Omega 3 for Treatment of Depression in Patients With Heart Failure |
| NCT02487771 | PHASE3 | COMPLETED | Kansas University DHA Outcome Study (KUDOS) Follow-Up |
| NCT02974348 | PHASE3 | COMPLETED | Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa |
| NCT04049916 | PHASE2/PHASE3 | COMPLETED | Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission |
| NCT04149106 | PHASE3 | UNKNOWN | Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin |
| NCT04844099 | PHASE3 | COMPLETED | Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia |
| NCT05946642 | PHASE3 | UNKNOWN | Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso |
| NCT06842524 | PHASE2 | RECRUITING | Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome |
| NCT07557927 | PHASE2 | NOT_YET_RECRUITING | A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus |
| NCT03396393 | PHASE2 | UNKNOWN | Exploratory Study of DHA in Systemic Lupus Erythematosus Patients |
| NCT03613844 | PHASE2 | COMPLETED | DHA Brain Delivery Trial |
| NCT04609098 | PHASE2 | COMPLETED | Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) |
| NCT05829187 | PHASE2 | COMPLETED | Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency |
| NCT06036030 | PHASE2 | COMPLETED | Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua |
| NCT06417099 | PHASE2 | COMPLETED | Efficacy of Dihydroartemisinin for Treating PCOS |
| NCT00988585 | PHASE1 | COMPLETED | Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil |
| NCT01670773 | PHASE1 | COMPLETED | A Study of CAT-1004 Biomarkers in Healthy Subjects |
| NCT02184637 | PHASE1 | COMPLETED | A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate |
| NCT06494488 | EARLY_PHASE1 | RECRUITING | Differential Thrombogenesis by EPA and DHA Mediated by HDL |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).